Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Tango Therapeutics (TNGX) FCF Margin: 2020-2025

Historic FCF Margin for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to -57.80%.

  • Tango Therapeutics' FCF Margin rose 23086.00% to -57.80% in Q3 2025 from the same period last year, while for Sep 2025 it was -220.70%, marking a year-over-year increase of 6323.00%. This contributed to the annual value of -314.38% for FY2024, which is 1280.00% up from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' FCF Margin is -57.80%, which was up 95.05% from -1,167.65% recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' FCF Margin ranged from a high of -44.10% in Q2 2021 and a low of -1,167.65% during Q2 2025.
  • Moreover, its 3-year median value for FCF Margin was -509.91% (2023), whereas its average is -498.04%.
  • In the last 5 years, Tango Therapeutics' FCF Margin surged by 40,568bps in 2023 and then plummeted by 104,726bps in 2025.
  • Quarterly analysis of 5 years shows Tango Therapeutics' FCF Margin stood at -307.87% in 2021, then tumbled by 14,926bps to -457.14% in 2022, then crashed by 5,277bps to -509.91% in 2023, then crashed by 38,324bps to -893.15% in 2024, then skyrocketed by 23,086bps to -57.80% in 2025.
  • Its last three reported values are -57.80% in Q3 2025, -1,167.65% for Q2 2025, and -774.26% during Q1 2025.